In a 6-month follow-up study with older diabetic patients, Sencan et al. [39] found out that adding a DPP-4 inhibitor to the patients’ treatments could effectively and significantly result in a positive effect on muscle strength, counteracting T2DM-related sarcopenia occurrence. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.